Previous 10 | Next 10 |
Theravance failed 3 trials last year. There was a major restructuring and change of focus. A small revenue stream from YUPELRI is its only positive, but that doesn't justify the valuation. For further details see: Theravance: All-Round Failure
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Theravance Biopharma, Inc. 2021 Q4 - Results - Earnings Call Presentation
Theravance Biopharma, Inc. (TBPH) Q4 2021 Earnings Conference Call February 23, 2022 5:00 PM ET Company Participants Gail Cohen – Vice President-Corporate Communications Rick Winningham – Chief Executive Officer Rhonda Farnum – Senior Vice President, Commercial and Medica...
Theravance Biopharma press release (NASDAQ:TBPH): Q4 GAAP EPS of -$0.43 misses by $0.12. Revenue of $14.95M (-20.2% Y/Y) beats by $1.39M. The company expects FY2022 R&D expense of $45M to $55M and SG&A expense of $35M to $45M. The company expects to be sustainably cash-flow positive b...
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update - Implied 35% share of YUPELRI® (revefenacin) net sales¹: $15.3M Q4 2021 up 13% from Q4 2020, $56.7M FY 2021 up 13% from FY 2020 - TRELEGY Q4 2021 gl...
AAN, ACA, OTCPK:ACLLF, AEM, AEVA, AGI, AHT, ALLO, ALR, AMED, ANSS, ARNA, AZUL, BAND, BBDC, BBWI, BCSF, BHP, BIRD, BKNG, BMA, BMRN, CCRN, CDEV, CHDN, CHK, CLOV, CMLS, CPE, CSV, CTRA, CW, DHC, DK, DKL, EBAY, EFC, OTCPK:EIFZF, EVH, EXR, FBRT, FIVN, FIX, FLGT, FLS, FNF, FRG, FTI, FUBO, GBT, GH, G...
Seth Klarman’s 13F portfolio value decreased from $10.88B to $10.13B this quarter. Baupost Group added Fiserv while dropping eBay and International Flavors & Fragrances. The portfolio continues to be heavily concentrated with the top three positions accounting for ~35% ...
Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (NYSE:OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (NASDAQ:VTGN) +8%. Losers: ProQR Therapeutics PRQR -72%. Senseonics SENS -19%. PetVivo P...
GlaxoSmithKline (NYSE:GSK) is speculated to be potentially targeting an acquisition of Theravance Biopharma (NASDAQ:TBPH). The "rumour mill" is talking about a potential GSK bid for Theravance (TBPH), according to the London Times. One hedge fund source said Sanofi (NASDAQ:SNY) could also be ...
Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 PR Newswire DUBLIN , Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2021 financial results...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 PR Newswire DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update...
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...